Abstract
Central nervous system hemangioblastomas are benign vascular tumours that may present sporadically or as manifestation of the von Hippel-Lindau (VHL) disease. VHL Syndrome is a rare autosomal dominant disorder characterized, besides hemangioblastomas, by susceptibility to multifocal and bilateral renal cell carcinoma and cysts, retinal angiomas, pheochromocytoma, epididymis cystoadenoma, pancreatic cysts and/or islet cell tumours. Germline mutations of VHL tumour suppressor gene cause the VHL disease, while somatic mutations have been associated with sporadic hemangioblastomas and clear-cell renal carcinomas. We identified an 11-bp duplication in the promoter region of the VHL gene in a VHL-affected individual. Functional analysis revealed that this variant affects the binding or the binding affinity of one or more transcription factors that regulate the transcription of VHL in vivo, reducing the endogenous levels of VHL mRNA. Moreover, consistent with the “two hits” model, microsatellite analysis of hemangioblastoma tissue from this patient revealed Allelic Imbalance for the chromosomal region near the VHL gene. We propose that these molecular events, through a loss of pVHL function, lead to the onset of the VHL-related tumours in that individual.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Catapano D, Muscarella LA, Guarnieri V, Zelante L, D’Angelo VA, D’Agruma L (2005) Hemangioblastomas of central nervous system: molecular genetic analysis and clinical management (discussion 1221). Neurosurgery 56(6):1215–1221
Choyke PL, Glenn GM, Wagner JP, Lubensky IA, Thakore K, Zbar B, Linehan WM, Walther MM (1997) Epididymal cystadenomas in von Hippel-Lindau disease. Urology 49(6):926–931
Choyke PL, Glenn GM, Walther MM, Patronas NJ, Linehan WM, Zbar B (1995) von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology 194(3):629–642
Clifford SC, Maher ER (2001) Von Hippel-Lindau disease: clinical and molecular perspectives. Adv Cancer Res 82:85–105
Crossey PA, Foster K, Richards FM, Phipps ME, Latif F, Tory K, Jones MH, Bentley E, Kumar R, Lerman MI, others (1994) Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet 93(1):53–58
Cybulski C, Krzystolik K, Maher ER, Richard S, Kurzawski G, Gronwald J, Lubinski J (1999) Long polymerase chain reaction in detection of germline deletions in the von Hippel-Lindau tumour suppressor gene. Hum Genet 105(4):333–336
Fiske J, Patel R, Kau E, Pappas JG, Garcia RA, Taneja SS (2005) Multifocal renal oncocytoma in a patient with Von Hippel-Lindau mutation. Urology 66(6):1320
Friedrich CA (2001) Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet 10(7):763–767
Gallou C, Chauveau D, Richard S, Joly D, Giraud S, Olschwang S, Martin N, Saquet C, Chretien Y, Mejean A, others (2004). Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions. Hum Mutat 24(3):215–224
Glasker S, Bender BU, Apel TW, van Velthoven V, Mulligan LM, Zentner J, Neumann HP (2001) Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry 70(5):644–648
Glenn G, Stolle C, Sgambati M, Choyke P, Hurley K, Peterson J, Manolatos C, al e. (1999) New mutations versus silent-carrier parentsas source of first generation diagnoses in a hereditary neoplastic disorder: von Hippel-Lindau disease. Proc Am Assoc Cancer Res 40:464
Glenn GM, Daniel LN, Choyke P, Linehan WM, Oldfield E, Gorin MB, Hosoe S, Latif F, Weiss G, Walther M, others (1991) Von Hippel-Lindau (VHL) disease: distinct phenotypes suggest more than one mutant allele at the VHL locus. Hum Genet 87(2):207–210
Kleihues P, Cavenee W (2000) Pathology and genetics of tumours of the nervous system: World Health Organization Classification of Tumours, Lyon
Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68(4):820–823
Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, Croce CM (2003) Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 63(13):3724–3728
Kuzmin I, Duh FM, Latif F, Geil L, Zbar B, Lerman MI (1995). Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene 10(11):2185–2194
Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, others (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260(5112):1317–1320
Lee JY, Dong SM, Park WS, Yoo NJ, Kim CS, Jang JJ, Chi JG, Zbar B, Lubensky IA, Linehan WM, others (1998) Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res 58(3):504–508
Lee S, Chen DY, Humphrey JS, Gnarra JR, Linehan WM, Klausner RD (1996) Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci USA 93(5):1770–1775
Lemeta S, Aalto Y, Niemela M, Jaaskelainen J, Sainio M, Kere J, Knuutila S, Bohling T (2002) Recurrent DNA sequence copy losses on chromosomal arm 6q in capillary hemangioblastoma. Cancer Genet Cytogenet 133(2):174–178
Linehan M, Zbar B, Klausner R (2001) The metabolic and molecular basis of inherited disease. In: Renal carcinoma, 8th edn. McGraw-Hill, New York, pp 907–929
Linehan WM, Lerman MI, Zbar B (1995) Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273(7):564–570
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25(4):402–408
Maddock IR, Moran A, Maher ER, Teare MD, Norman A, Payne SJ, Whitehouse R, Dodd C, Lavin M, Hartley N, others (1996) A genetic register for von Hippel-Lindau disease. J Med Genet 33(2):120–127
Maher ER, Kaelin WG Jr (1997) von Hippel-Lindau disease. Med (Baltimore) 76(6):381–391
Manski TJ, Heffner DK, Glenn GM, Patronas NJ, Pikus AT, Katz D, Lebovics R, Sledjeski K, Choyke PL, Zbar B, others (1997) Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA 277(18):1461–1466
Martella M, Salviati L, Casarin A, Trevisson E, Opocher G, Polli R, Gross D, Murgia A (2006) Molecular analysis of two uncharacterized sequence variants of the VHL gene. J Hum Genet
Prowse AH, Webster AR, Richards FM, Richard S, Olschwang S, Resche F, Affara NA, Maher ER (1997) Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet 60(4):765–771
Richards FM, Schofield PN, Fleming S, Maher ER (1996) Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Hum Mol Genet 5(5):639–644
Skotheim RI, Diep CB, Kraggerud SM, Jakobsen KS, Lothe RA (2001) Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet Cytogenet 127(1):64–70
Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, Pack S, Hurley K, Andrey C, Klausner R, others (1998) Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 12(6):417–423
Teh BT, Blennow E, Giraud S, Sahlen S, Hii SI, Brookwell R, Brauch H, Nordenskjold M, Larsson C, Nicol D (1998). Bilateral multiple renal oncocytomas and cysts associated with a constitutional translocation (8;9)(q24.1;q34.3) and a rare constitutional VHL missense substitution. Genes Chromosomes Cancer 21(3):260–264
Tse JY, Wong JH, Lo KW, Poon WS, Huang DP, Ng HK (1997) Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am J Clin Pathol 107(4):459–466
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3(7):RESEARCH0034
Vortmeyer AO, Gnarra JR, Emmert-Buck MR, Katz D, Linehan WM, Oldfield EH, Zhuang Z (1997) von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol 28(5):540–543
Webster AR, Richards FM, MacRonald FE, Moore AT, Maher ER (1998) An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genet 63(4):1025–1035
Woodward ER, Buchberger A, Clifford SC, Hurst LD, Affara NA, Maher ER (2000) Comparative sequence analysis of the VHL tumor suppressor gene. Genomics 65(3):253–265
Zatyka M, Morrissey C, Kuzmin I, Lerman MI, Latif F, Richards FM, Maher ER (2002) Genetic and functional analysis of the von Hippel-Lindau (VHL) tumour suppressor gene promoter. J Med Genet 39(7):463–472
Acknowledgments
We are grateful to Luigi Bisceglia, Samuel Deutsch, and Alexandre Reymond for technical advice and critical reading of the manuscript. This study was supported by the Italian Ministry of Health (Ricerca Corrente 2005). The authors declare no potential conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Muscarella, L.A., Barbano, R., Augello, B. et al. An 11-bp duplication in the promoter region of the VHL gene in a patient with cerebellar hemangioblastoma and renal oncocytoma. J Hum Genet 52, 485–491 (2007). https://doi.org/10.1007/s10038-007-0138-1
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s10038-007-0138-1
